Metabolic syndrome in rheumatoid arthritis: case control study

BMC Musculoskeletal Disorders

Najia Hajjaj-Hassouni¹  Rachid Bahiri¹  Asmaa Hari¹  Racha Lahlou¹  Mariam Mengat¹  Samira Rostom¹ 

[1] Department of Rheumatology, University Mohammed V Souissi. Faculty of Medicine and Pharmacy. El Ayachi hospital, University Hospital of Rabat-Sale, PO Box: 10000, Sale, Morocco

关键词: Disease activity;    Rheumatoid arthritis;    Metabolic syndrome;   

Others  :  1132732
DOI  :  10.1186/1471-2474-14-147

 received in 2012-09-20, accepted in 2013-04-15,  发布年份 2013

【 摘 要 】

Background

Metabolic syndrome, a cluster of classical cardiovascular risk factors, including hypertension, obesity, glucose intolerance, and dyslipidemia is highly prevalent in patients with rheumatoid arthritis (RA). The aim of the study was to assess the frequency of metabolic syndrome (MS) in RA patients, and to evaluate the relationships between metabolic syndrome and RA.

Methods

The study was conducted on 120 RA patients according to the 1987 revised American College of Rheumatology classification criteria, and 100 age and sex matched apparently healthy controls. The frequency of metabolic syndrome was assessed using six Metabolic Syndrome definitions (Joint Consensus 2009, National Cholesterol Education Programme 2004 and 2001, International Diabetes Federation, World Health Organisation and European Group for Study of Insulin Resistance). Logistic regression was used to identify independent predictors of metabolic Syndrome.

Results

The frequency of metabolic syndrome varied from 18 to 48.6% in RA according to the definition used and was significantly higher than controls (for all definitions p<0.05). In multivariate analysis, higher ESR was independently associated with the presence of Met S (OR =1.36; CI: 1.18–2.12; p = 0.03). Glucocorticoid use, but not other disease modifying anti-rheumatic drugs (DMARDs), values remained significant independent predictors of the presence of metabolic syndrome in RA patients (OR = 1.45; CI: 1.12–2.14; p = 0.04).

Conclusions

In summary, the frequency of metabolic syndrome in RA varies according to the definition used and was significantly higher compared to controls (for all definitions p<0.05). Higher systemic inflammatory marker, and glucocorticoids use were independent predictors associated with the presence of metabolic syndrome in patients with RA. These findings suggest that physicians should screen for metabolic syndrome in patients with RA to control its components and therefore reduce the risk of cardiovascular disease in these patients.

【 授权许可】

   
2013 rostom et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Rall LC, Roubenoff R: Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004, 43:1219-1223.
• [2]Giles JT, Bartlett SJ, Andersen RE, Fontaine KR, Bathon JM: Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum 2008, 59:1407-1415.
• [3]Goodson N, Marks J, Lunt M, Symmons D: Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980 s and 1990s. Ann Rheum Dis 2005, 64:1595-1601.
• [4]Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT: EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
• [5]Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM: Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardio 2002, 40:937-943.
• [6]Eva K, Panagiota Pervanidou, Gregory Kaltsas and George Chrousos: Metabolic syndrome: definitions and controversies. BMC Med 2011, 9:48. BioMed Central Full Text
• [7]Dessein PH, Tobias M, Veller MG: Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006, 33:2425-2432.
• [8]Crowson CS, Myasoedova E, Davis JM, Matteson EL, Roger VL, Therneau TM, Fitz-Gibbon P, Rodeheffer RJ, Gabriel SE: Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 2011, 38(1):29-35.
• [9]Hajjaj-Hassouni N, Al-Badi M, Al-Heresh A, Al-Emadi S, El Bawendi A, El Garf A, El Hadidi K, Halabi H, Hammoudeh M, El Hassani S, Al Maaini M, Nahar I, Ladjouze Rezig A, Sellami S, Sweiri W, Alswailem R, Traub B, Uthman I, Van Duuren E, Zakraoui L, El Zorkany B, Carmona L, Dougados M: The practical value of biologics registries in Africa and Middle East: challenges and opportunities. Clin Rheumatol 2012, 31(3):407-16.
• [10]Benbouazza K, Benchekroun B, Rkain H, Amine B, Bzami F, Benbrahim L, Atouf O, Essakalli M, Abouqal R, Dougados M, Hajjaj-Hassouni N: Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study. BMC Musculoskelet Disord 2011 Nov 23, 12:266. BioMed Central Full Text
• [11]Ibn Yacoub Y, Amine B, Laatiris A, Wafki F, Znat F, Hajjaj-Hassouni N: Prevalence of overweight in Moroccan patients with rheumatoid arthritis and its relationships with disease features. Clin Rheumatol 2012 Mar, 31(3):479-82.
• [12]Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N: Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life. Clin Rheumatol 2012 Feb, 31(2):329-34.
• [13]Kalla AA, Tikly M: Rheumatoid arthritis in the developing world. Best Pract Res Clin Rheumatol 2003, 17(5):863-875.
• [14]Badsha H, Kong KO: Tak PP (2008) Rheumatoid arthritis in the United Arab Emirates. Clin Rheumatol 2008, 27(6):739-742.
• [15]Naranjo A, Toloza S, Naranjo A, Toloza S, Guimaraes Da Silveira I, Lazovskis J, Hetland ML, Hamoud H, Peets T, Mäkinen H, Gossec L, Herborn G, Skopouli FN, Rojkovich B, Aggarwal A, Minnock P, Cazzato M, Yamanaka H, Oyoo O, Rexhepi S, Andersone D, Baranauskaite A, Hajjaj-Hassouni N, Jacobs JW, Haugeberg G, Sierakowski S, Ionescu R, Karateew D, Dimic A, Henrohn D, Gogus F, Badsha H, Choy E, Bergman M, Sokka T: Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Clin Exp Rheumatol 2010, 28(6):820-7.
• [16]Solomon A, Christian BF, Norton GR, Woodiwiss AJ, Dessein PH: Risk factor profiles for atherosclerotic cardiovascular disease in black and other Africans with established rheumatoid arthritis. J Rheumatol 2010 May, 37(5):953-60.
• [17]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
• [18]Prevoo ML, van’t Hof MA, Kupper HH, van Leeuwen MA, van de Putte LB, van Riel L: Modified disease activity scores that includes twenty-eightjoint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
• [19]Abourazzak FE, Benbouazza K, Amine B, Bahiri R, Lazrak N, Bzami F, Jroundi I, Abouqal R, Guillemin F, Hajjaj-Hassouni N: Psychometric evaluation of a Moroccan version of health assessment questionnaire for use in Moroccan patients with rheumatoid arthritis. Rheumatol Int 2008, 28(12):1197-203.
• [20]Physical Status the Use and Interpretation of Anthropometry: In Report of a WHO expert committee. World Health Organ Tech Rep Ser 1995, 854:1-452.
• [21]Alberti KG, Zimmet P, Shaw J: Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation Diabet Med 2006, 23(5):469-80.
• [22]Reilly MP, Rader DJ: The metabolic syndrome: more than the sum of its parts? Circulation 2003, 108:1546-1551.
• [23]Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. Diabet Med 1999, 16:442-443.
• [24]Alberti KGMM, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
• [25]NCEP Expert Panel: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
• [26]Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
• [27]Alberti KG, Zimmet P, Shaw J: The metabolic syndrome: a new worldwide definition. Lancet 2005, 366:1059-1062.
• [28]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [29]Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, Ganotakis ES, Boumpas DT: Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, crosssectional, controlled, study. Ann Rheum Dis 2007, 66:28-33.
• [30]Gremese E, Ferraccioli G: The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011, 10(10):582-9.
• [31]Sunita D, Rebecca H, Jo W, James V, Kamal G, Lei D, Butler MG: Metabolic syndrome in South Asian immigrants: more than low HDL requiring aggressive management. Lipids Health Dis 2011, 10:45. BioMed Central Full Text
• [32]Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A: Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008, 196:756-63.
• [33]Zonana-Nacach A, Santana-Sahagun E, Jimenez-Balderas FJ, Coronel C: Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol 2008, 14:74-77.
• [34]Raterman HG, van Eijk IC, Voskuy AE, Peter MJ, Dijkmans BA, van Halm VP, Simsel S, Lems WF, Nurmohamed MT: The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional study. Ann Rheum Dis 2010, 69:39-42.
• [35]Toms T, Panoulas V, John H, Douglas KM, Kitas GD: Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009, 11(4):R110. BioMed Central Full Text
• [36]Elkan AC, Hakansson N, Frostegard J, Cederholm T, Hafstrom I: Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2009, 11(4):R37.
• [37]le Son NT, Kunii D, Hung NTK, Sakai T, Yamamoto S: The metabolic syndrome: prevalence and risk factors in the urban population of Ho Chi Minh City. Diabetes Res Clin Pract 2005, 67:243-250.
• [38]Alexander CM, Landsman PB, Grundy SM: The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Obes Metab 2008, 10:246-250.
• [39]Shahin D, Eltoraby E, Mesbah A, Houssen M: Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 2010, 43:661-665.
• [40]Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, Kitas GD: Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009, 16:188-19.
• [41]Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Kitas GD: Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2008, 10:R145. BioMed Central Full Text
• [42]Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M: Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004, 31:867-74.
• [43]Bijlsma JWJ, van der Goes MC, Hoes JN, Jacobs JWG, Buttgereit F, Kirwan J: Low-dose glucorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann N Y Acad Sci 2010, 1193:123-126.
• [44]Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG: Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008, 371:1927-1935.